# Symbicort Onset of Action 2

> **NCT00646009** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 48 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** budesonide/formoterol
- **DRUG:** fluticasone/salmeterol
- **DRUG:** albuterol

## Key facts

- **NCT ID:** NCT00646009
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2003-08
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00646009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00646009, "Symbicort Onset of Action 2". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00646009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*